Galderma says ARCADIA extension data show Nemluvio sustains atopic dermatitis gains through three years

Galderma flagged new three-year ARCADIA extension results for Nemluvio in moderate-to-severe atopic dermatitis, scheduled for presentation at EADV 2026. Data indicate durable disease control with sustained improvements in skin symptoms, itch, sleep disruption, and quality of life. Treatment remained well-tolerated over the period, with no new safety concerns versus prior long-term updates. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galderma Group AG published the original content used to generate this news brief via (Ref. ID: 20260929663019) on September 30, 2026, and is solely responsible for the information contained therein. (C)